Skip to main content
Top
Published in: Molecular Cancer 1/2014

Open Access 01-12-2014 | Research

Sensitivity of leukemic T-cell lines to arsenic trioxide cytotoxicity is dependent on the induction of phosphatase B220/CD45R expression at the cell surface

Authors: Mohcine Benbijja, Amine Mellouk, Pierre Bobé

Published in: Molecular Cancer | Issue 1/2014

Login to get access

Abstract

Background

Arsenic trioxide (As2O3) is highly effective in treating acute promyelocytic leukemia (APL), but shows more variable therapeutic efficacy for other types of hematological malignancies. Previously, we reported that As2O3 selectively eliminates pathogenic B220-expressing T cells in autoimmune MRL/lpr mice. We investigated herein the relationship between As2O3 sensitivity of leukemic T-cell lines and the expression levels of the B220 isoform of transmembrane tyrosine phosphatase CD45.

Methods

GSH content, O2- production, and B220, HSP70, Fas and FasL membrane expression was measured by flow cytometry. Subcellular localization of B220 was determined by imaging flow cytometry. Cell death was analyzed by morphological changes, annexin V and propidium iodide staining, and caspase 8 and 9 activation. B220 mRNA expression was analyzed by RT-PCR. Activated NF-κB p50 was quantified by a DNA binding ELISA.

Results

We selected human (Jurkat, Jurkat variant J45.01, HPB-ALL) and mouse (EL-4, BW5147, L1210) T-cell lines for their marked differences in As2O3 sensitivity over a large range of doses (1 to 20 μM). Differences in redox status cannot explain the dramatic differences in As2O3 sensitivity observed among the T-cell lines. Unexpectedly, we found that B220 is differentially induced on As2O3-treated T-cell lines. As2O3 treatment for 24 h induced low (HPB-ALL), intermediate (Jurkat) and high (EL-4, BW5147) levels of B220 membrane expression, membrane-bound HSP70 and cell death, but inhibited NF-κB p50 nuclear translocation. When high levels of B220 expression were achieved with low doses of As2O3, the T-cell lines died by apoptosis only. When high doses of As2O3 were required to induce B220 expression, leukemic T cells died by both apoptosis and necrosis.

Conclusions

Cellular redox status is not essential for As2O3 sensitivity of leukemic T cells, suggesting the existence of additional factors determining their sensitivity to As2O3 cytotoxicity. Phosphatase B220 could be such a factor of sensitivity. As2O3 treatment inhibits NF-κB p50 nuclear translocation, and induces B220 expression and cell death in a dose and time dependent manner. The levels of B220 induction on leukemic T cells strictly correlate with both the extent and form of cell death, B220 might therefore play a checkpoint role in death pathways.
Appendix
Available only for authorised users
Literature
1.
go back to reference Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, Chen Y, Zhou L, Fang ZW, Wang YT, Ma J, Zhang P, Zhang TD, Chen SJ, Chen Z, Wang ZY: Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997, 89: 3354-3360.PubMed Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, Chen Y, Zhou L, Fang ZW, Wang YT, Ma J, Zhang P, Zhang TD, Chen SJ, Chen Z, Wang ZY: Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997, 89: 3354-3360.PubMed
2.
go back to reference Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, Pandolfi PP, Warrell RP: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 1998, 339: 1341-1348. 10.1056/NEJM199811053391901CrossRefPubMed Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, Pandolfi PP, Warrell RP: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 1998, 339: 1341-1348. 10.1056/NEJM199811053391901CrossRefPubMed
3.
go back to reference Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, Wu W, Zhang FQ, Chen Y, Zhou L, Li JM, Zeng XY, Yang RR, Yuan MM, Ren MY, Gu FY, Cao Q, Gu BW, Su XY, Chen GQ, Xiong SM, Zhang TD, Waxman S, Wang ZY, Chen Z, Hu J, Shen ZX, Chen SJ: Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood. 1999, 94: 3315-3324.PubMed Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, Wu W, Zhang FQ, Chen Y, Zhou L, Li JM, Zeng XY, Yang RR, Yuan MM, Ren MY, Gu FY, Cao Q, Gu BW, Su XY, Chen GQ, Xiong SM, Zhang TD, Waxman S, Wang ZY, Chen Z, Hu J, Shen ZX, Chen SJ: Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood. 1999, 94: 3315-3324.PubMed
4.
go back to reference Lallemand-Breitenbach V, Zhu J, Chen Z, de The H: Curing APL through PML/RARA degradation by As2O3. Trends Mol Med. 2012, 18: 36-42. 10.1016/j.molmed.2011.10.001CrossRefPubMed Lallemand-Breitenbach V, Zhu J, Chen Z, de The H: Curing APL through PML/RARA degradation by As2O3. Trends Mol Med. 2012, 18: 36-42. 10.1016/j.molmed.2011.10.001CrossRefPubMed
5.
go back to reference Miller WH, Schipper HM, Lee JS, Singer J, Waxman S: Mechanisms of action of arsenic trioxide. Cancer Res. 2002, 62: 3893-3903.PubMed Miller WH, Schipper HM, Lee JS, Singer J, Waxman S: Mechanisms of action of arsenic trioxide. Cancer Res. 2002, 62: 3893-3903.PubMed
6.
go back to reference Lallemand-Breitenbach V, Jeanne M, Benhenda S, Nasr R, Lei M, Peres L, Zhou J, Zhu J, Raught B, de The H: Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol. 2008, 10: 547-555. 10.1038/ncb1717CrossRefPubMed Lallemand-Breitenbach V, Jeanne M, Benhenda S, Nasr R, Lei M, Peres L, Zhou J, Zhu J, Raught B, de The H: Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol. 2008, 10: 547-555. 10.1038/ncb1717CrossRefPubMed
7.
go back to reference Tatham MH, Geoffroy MC, Shen L, Plechanovova A, Hattersley N, Jaffray EG, Palvimo JJ, Hay RT: RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat Cell Biol. 2008, 10: 538-546. 10.1038/ncb1716CrossRefPubMed Tatham MH, Geoffroy MC, Shen L, Plechanovova A, Hattersley N, Jaffray EG, Palvimo JJ, Hay RT: RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat Cell Biol. 2008, 10: 538-546. 10.1038/ncb1716CrossRefPubMed
8.
go back to reference Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X, Han ZG, Ni JH, Shi GY, Jia PM, Liu MM, He KL, Niu C, Ma J, Zhang P, Zhang TD, Paul P, Naoe T, Kitamura K, Miller W, Waxman S, Wang ZY, de The H, Chen SJ, Chen Z: Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood. 1997, 89: 3345-3353.PubMed Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X, Han ZG, Ni JH, Shi GY, Jia PM, Liu MM, He KL, Niu C, Ma J, Zhang P, Zhang TD, Paul P, Naoe T, Kitamura K, Miller W, Waxman S, Wang ZY, de The H, Chen SJ, Chen Z: Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood. 1997, 89: 3345-3353.PubMed
9.
go back to reference Yang CH, Kuo ML, Chen JC, Chen YC: Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells. Br J Cancer. 1999, 81: 796-799. 10.1038/sj.bjc.6690766PubMedCentralCrossRefPubMed Yang CH, Kuo ML, Chen JC, Chen YC: Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells. Br J Cancer. 1999, 81: 796-799. 10.1038/sj.bjc.6690766PubMedCentralCrossRefPubMed
10.
go back to reference Dai J, Weinberg RS, Waxman S, Jing Y: Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood. 1999, 93: 268-277.PubMed Dai J, Weinberg RS, Waxman S, Jing Y: Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood. 1999, 93: 268-277.PubMed
11.
go back to reference Chou WC, Jie C, Kenedy AA, Jones RJ, Trush MA, Dang CV: Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells. Proc Natl Acad Sci U S A. 2004, 101: 4578-4583. 10.1073/pnas.0306687101PubMedCentralCrossRefPubMed Chou WC, Jie C, Kenedy AA, Jones RJ, Trush MA, Dang CV: Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells. Proc Natl Acad Sci U S A. 2004, 101: 4578-4583. 10.1073/pnas.0306687101PubMedCentralCrossRefPubMed
12.
go back to reference Dilda PJ, Hogg PJ: Arsenical-based cancer drugs. Cancer Treat Rev. 2007, 33: 542-564. 10.1016/j.ctrv.2007.05.001CrossRefPubMed Dilda PJ, Hogg PJ: Arsenical-based cancer drugs. Cancer Treat Rev. 2007, 33: 542-564. 10.1016/j.ctrv.2007.05.001CrossRefPubMed
13.
go back to reference Bobé P, Bonardelle D, Benihoud K, Opolon P, Chelbi-Alix MK: Arsenic trioxide: a promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL/lpr mice. Blood. 2006, 108: 3967-3975. 10.1182/blood-2006-04-020610CrossRefPubMed Bobé P, Bonardelle D, Benihoud K, Opolon P, Chelbi-Alix MK: Arsenic trioxide: a promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL/lpr mice. Blood. 2006, 108: 3967-3975. 10.1182/blood-2006-04-020610CrossRefPubMed
14.
go back to reference Le Gall SM, Legrand J, Benbijja M, Safya H, Benihoud K, Kanellopoulos JM, Bobé P: Loss of P2X7 receptor plasma membrane expression and function in pathogenic B220+ double-negative T lymphocytes of autoimmune MRL/lpr mice. PLoS One. 2012, 7: e52161- 10.1371/journal.pone.0052161PubMedCentralCrossRefPubMed Le Gall SM, Legrand J, Benbijja M, Safya H, Benihoud K, Kanellopoulos JM, Bobé P: Loss of P2X7 receptor plasma membrane expression and function in pathogenic B220+ double-negative T lymphocytes of autoimmune MRL/lpr mice. PLoS One. 2012, 7: e52161- 10.1371/journal.pone.0052161PubMedCentralCrossRefPubMed
15.
go back to reference Renno T, Attinger A, Rimoldi D, Hahne M, Tschopp J, MacDonald HR: Expression of B220 on activated T cell blasts precedes apoptosis. Eur J Immunol. 1998, 28: 540-547. 10.1002/(SICI)1521-4141(199802)28:02<540::AID-IMMU540>3.0.CO;2-YCrossRefPubMed Renno T, Attinger A, Rimoldi D, Hahne M, Tschopp J, MacDonald HR: Expression of B220 on activated T cell blasts precedes apoptosis. Eur J Immunol. 1998, 28: 540-547. 10.1002/(SICI)1521-4141(199802)28:02<540::AID-IMMU540>3.0.CO;2-YCrossRefPubMed
16.
go back to reference Bleesing JJ, Morrow MR, Uzel G, Fleisher TA: Human T cell activation induces the expression of a novel CD45 isoform that is analogous to murine B220 and is associated with altered O-glycan synthesis and onset of apoptosis. Cell Immunol. 2001, 213: 72-81. 10.1006/cimm.2001.1865CrossRefPubMed Bleesing JJ, Morrow MR, Uzel G, Fleisher TA: Human T cell activation induces the expression of a novel CD45 isoform that is analogous to murine B220 and is associated with altered O-glycan synthesis and onset of apoptosis. Cell Immunol. 2001, 213: 72-81. 10.1006/cimm.2001.1865CrossRefPubMed
17.
go back to reference Hermiston ML, Xu Z, Weiss A: CD45: a critical regulator of signaling thresholds in immune cells. Annu Rev Immunol. 2003, 21: 107-137. 10.1146/annurev.immunol.21.120601.140946CrossRefPubMed Hermiston ML, Xu Z, Weiss A: CD45: a critical regulator of signaling thresholds in immune cells. Annu Rev Immunol. 2003, 21: 107-137. 10.1146/annurev.immunol.21.120601.140946CrossRefPubMed
19.
go back to reference Rhee I, Veillette A: Protein tyrosine phosphatases in lymphocyte activation and autoimmunity. Nat Immunol. 2012, 13: 439-447. 10.1038/ni.2246CrossRefPubMed Rhee I, Veillette A: Protein tyrosine phosphatases in lymphocyte activation and autoimmunity. Nat Immunol. 2012, 13: 439-447. 10.1038/ni.2246CrossRefPubMed
20.
go back to reference Klaus SJ, Sidorenko SP, Clark EA: CD45 ligation induces programmed cell death in T and B lymphocytes. J Immunol. 1996, 156: 2743-2753.PubMed Klaus SJ, Sidorenko SP, Clark EA: CD45 ligation induces programmed cell death in T and B lymphocytes. J Immunol. 1996, 156: 2743-2753.PubMed
21.
go back to reference Stillman BN, Hsu DK, Pang M, Brewer CF, Johnson P, Liu FT, Baum LG: Galectin-3 and galectin-1 bind distinct cell surface glycoprotein receptors to induce T cell death. J Immunol. 2006, 176: 778-789. 10.4049/jimmunol.176.2.778CrossRefPubMed Stillman BN, Hsu DK, Pang M, Brewer CF, Johnson P, Liu FT, Baum LG: Galectin-3 and galectin-1 bind distinct cell surface glycoprotein receptors to induce T cell death. J Immunol. 2006, 176: 778-789. 10.4049/jimmunol.176.2.778CrossRefPubMed
22.
go back to reference Clark MC, Baum LG: T cells modulate glycans on CD43 and CD45 during development and activation, signal regulation, and survival. Ann N Y Acad Sci. 2012, 1253: 58-67. 10.1111/j.1749-6632.2011.06304.xPubMedCentralCrossRefPubMed Clark MC, Baum LG: T cells modulate glycans on CD43 and CD45 during development and activation, signal regulation, and survival. Ann N Y Acad Sci. 2012, 1253: 58-67. 10.1111/j.1749-6632.2011.06304.xPubMedCentralCrossRefPubMed
23.
go back to reference Davison K, Mann KK, Waxman S, Miller WH: JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells. Blood. 2004, 103: 3496-3502. 10.1182/blood-2003-05-1412CrossRefPubMed Davison K, Mann KK, Waxman S, Miller WH: JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells. Blood. 2004, 103: 3496-3502. 10.1182/blood-2003-05-1412CrossRefPubMed
24.
go back to reference Pelicano H, Feng L, Zhou Y, Carew JS, Hileman EO, Plunkett W, Keating MJ, Huang P: Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J Biol Chem. 2003, 278: 37832-37839. 10.1074/jbc.M301546200CrossRefPubMed Pelicano H, Feng L, Zhou Y, Carew JS, Hileman EO, Plunkett W, Keating MJ, Huang P: Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J Biol Chem. 2003, 278: 37832-37839. 10.1074/jbc.M301546200CrossRefPubMed
25.
go back to reference Pelicano H, Carney D, Huang P: ROS stress in cancer cells and therapeutic implications. Drug Resist Updat. 2004, 7: 97-110. 10.1016/j.drup.2004.01.004CrossRefPubMed Pelicano H, Carney D, Huang P: ROS stress in cancer cells and therapeutic implications. Drug Resist Updat. 2004, 7: 97-110. 10.1016/j.drup.2004.01.004CrossRefPubMed
26.
go back to reference Multhoff G, Botzler C, Wiesnet M, Muller E, Meier T, Wilmanns W, Issels RD: A stress-inducible 72-kDa heat-shock protein (HSP72) is expressed on the surface of human tumor cells, but not on normal cells. Int J Cancer. 1995, 61: 272-279. 10.1002/ijc.2910610222CrossRefPubMed Multhoff G, Botzler C, Wiesnet M, Muller E, Meier T, Wilmanns W, Issels RD: A stress-inducible 72-kDa heat-shock protein (HSP72) is expressed on the surface of human tumor cells, but not on normal cells. Int J Cancer. 1995, 61: 272-279. 10.1002/ijc.2910610222CrossRefPubMed
27.
go back to reference Stangl S, Gehrmann M, Riegger J, Kuhs K, Riederer I, Sievert W, Hube K, Mocikat R, Dressel R, Kremmer E, Pockley AG, Friedrich L, Vigh L, Skerra A, Multhoff G: Targeting membrane heat-shock protein 70 (Hsp70) on tumors by cmHsp70.1 antibody. Proc Natl Acad Sci U S A. 2011, 108: 733-738. 10.1073/pnas.1016065108PubMedCentralCrossRefPubMed Stangl S, Gehrmann M, Riegger J, Kuhs K, Riederer I, Sievert W, Hube K, Mocikat R, Dressel R, Kremmer E, Pockley AG, Friedrich L, Vigh L, Skerra A, Multhoff G: Targeting membrane heat-shock protein 70 (Hsp70) on tumors by cmHsp70.1 antibody. Proc Natl Acad Sci U S A. 2011, 108: 733-738. 10.1073/pnas.1016065108PubMedCentralCrossRefPubMed
28.
go back to reference Sancho D, Gomez M, Sanchez-Madrid F: CD69 is an immunoregulatory molecule induced following activation. Trends Immunol. 2005, 26: 136-140. 10.1016/j.it.2004.12.006CrossRefPubMed Sancho D, Gomez M, Sanchez-Madrid F: CD69 is an immunoregulatory molecule induced following activation. Trends Immunol. 2005, 26: 136-140. 10.1016/j.it.2004.12.006CrossRefPubMed
29.
go back to reference McCafferty-Grad J, Bahlis NJ, Krett N, Aguilar TM, Reis I, Lee KP, Boise LH: Arsenic trioxide uses caspase-dependent and caspase-independent death pathways in myeloma cells. Mol Cancer Ther. 2003, 2: 1155-1164.PubMed McCafferty-Grad J, Bahlis NJ, Krett N, Aguilar TM, Reis I, Lee KP, Boise LH: Arsenic trioxide uses caspase-dependent and caspase-independent death pathways in myeloma cells. Mol Cancer Ther. 2003, 2: 1155-1164.PubMed
30.
go back to reference Scholz C, Wieder T, Starck L, Essmann F, Schulze-Osthoff K, Dorken B, Daniel PT: Arsenic trioxide triggers a regulated form of caspase-independent necrotic cell death via the mitochondrial death pathway. Oncogene. 2005, 24: 1904-1913. 10.1038/sj.onc.1208233CrossRefPubMed Scholz C, Wieder T, Starck L, Essmann F, Schulze-Osthoff K, Dorken B, Daniel PT: Arsenic trioxide triggers a regulated form of caspase-independent necrotic cell death via the mitochondrial death pathway. Oncogene. 2005, 24: 1904-1913. 10.1038/sj.onc.1208233CrossRefPubMed
31.
go back to reference Perkins ND: The diverse and complex roles of NF-kappaB subunits in cancer. Nat Rev Cancer. 2012, 12: 121-132.PubMed Perkins ND: The diverse and complex roles of NF-kappaB subunits in cancer. Nat Rev Cancer. 2012, 12: 121-132.PubMed
32.
go back to reference El-Sabban ME, Nasr R, Dbaibo G, Hermine O, Abboushi N, Quignon F, Ameisen JC, Bex F, de The H, Bazarbachi A: Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappa B activation. Blood. 2000, 96: 2849-2855.PubMed El-Sabban ME, Nasr R, Dbaibo G, Hermine O, Abboushi N, Quignon F, Ameisen JC, Bex F, de The H, Bazarbachi A: Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappa B activation. Blood. 2000, 96: 2849-2855.PubMed
33.
go back to reference Bornhauser BC, Bonapace L, Lindholm D, Martinez R, Cario G, Schrappe M, Niggli FK, Schafer BW, Bourquin JP: Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway. Blood. 2007, 110: 2084-2091. 10.1182/blood-2006-12-060970CrossRefPubMed Bornhauser BC, Bonapace L, Lindholm D, Martinez R, Cario G, Schrappe M, Niggli FK, Schafer BW, Bourquin JP: Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway. Blood. 2007, 110: 2084-2091. 10.1182/blood-2006-12-060970CrossRefPubMed
34.
go back to reference Tenev T, Bianchi K, Darding M, Broemer M, Langlais C, Wallberg F, Zachariou A, Lopez J, MacFarlane M, Cain K, Meier P: The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol Cell. 2011, 43: 432-448. 10.1016/j.molcel.2011.06.006CrossRefPubMed Tenev T, Bianchi K, Darding M, Broemer M, Langlais C, Wallberg F, Zachariou A, Lopez J, MacFarlane M, Cain K, Meier P: The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol Cell. 2011, 43: 432-448. 10.1016/j.molcel.2011.06.006CrossRefPubMed
35.
go back to reference Le Gall SM, Bobé P, Reiss K, Horiuchi K, Niu XD, Lundell D, Gibb DR, Conrad D, Saftig P, Blobel CP: ADAMs 10 and 17 represent differentially regulated components of a general shedding machinery for membrane proteins such as transforming growth factor alpha, L-Selectin, and tumor necrosis factor alpha. Mol Biol Cell. 2009, 20: 1785-1794. 10.1091/mbc.E08-11-1135PubMedCentralCrossRefPubMed Le Gall SM, Bobé P, Reiss K, Horiuchi K, Niu XD, Lundell D, Gibb DR, Conrad D, Saftig P, Blobel CP: ADAMs 10 and 17 represent differentially regulated components of a general shedding machinery for membrane proteins such as transforming growth factor alpha, L-Selectin, and tumor necrosis factor alpha. Mol Biol Cell. 2009, 20: 1785-1794. 10.1091/mbc.E08-11-1135PubMedCentralCrossRefPubMed
36.
go back to reference Zhu XH, Shen YL, Jing YK, Cai X, Jia PM, Huang Y, Tang W, Shi GY, Sun YP, Dai J, Wang ZY, Chen SJ, Zhang TD, Waxman S, Chen Z, Chen GQ: Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst. 1999, 91: 772-778. 10.1093/jnci/91.9.772CrossRefPubMed Zhu XH, Shen YL, Jing YK, Cai X, Jia PM, Huang Y, Tang W, Shi GY, Sun YP, Dai J, Wang ZY, Chen SJ, Zhang TD, Waxman S, Chen Z, Chen GQ: Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst. 1999, 91: 772-778. 10.1093/jnci/91.9.772CrossRefPubMed
37.
go back to reference Michel L, Dupuy A, Jean-Louis F, Sors A, Poupon J, Viguier M, Musette P, Dubertret L, Degos L, Dombret H, Bachelez H: Arsenic trioxide induces apoptosis of cutaneous T cell lymphoma cells: evidence for a partially caspase-independent pathway and potentiation by ascorbic acid (vitamin C). J Invest Dermatol. 2003, 121: 881-893. 10.1046/j.1523-1747.2003.12479.xCrossRefPubMed Michel L, Dupuy A, Jean-Louis F, Sors A, Poupon J, Viguier M, Musette P, Dubertret L, Degos L, Dombret H, Bachelez H: Arsenic trioxide induces apoptosis of cutaneous T cell lymphoma cells: evidence for a partially caspase-independent pathway and potentiation by ascorbic acid (vitamin C). J Invest Dermatol. 2003, 121: 881-893. 10.1046/j.1523-1747.2003.12479.xCrossRefPubMed
38.
go back to reference Bazarbachi A, El-Sabban ME, Nasr R, Quignon F, Awaraji C, Kersual J, Dianoux L, Zermati Y, Haidar JH, Hermine O, de The H: Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood. 1999, 93: 278-283.PubMed Bazarbachi A, El-Sabban ME, Nasr R, Quignon F, Awaraji C, Kersual J, Dianoux L, Zermati Y, Haidar JH, Hermine O, de The H: Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood. 1999, 93: 278-283.PubMed
39.
go back to reference Chang J, Voorhees P, Kolesar J, Ahuja H, Sanchez F, Rodriguez G, Kim K, Werndli J, Bailey H, Kahl B: Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study. Hematol Oncol. 2009, 27: 11-16.PubMedCentralCrossRefPubMed Chang J, Voorhees P, Kolesar J, Ahuja H, Sanchez F, Rodriguez G, Kim K, Werndli J, Bailey H, Kahl B: Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study. Hematol Oncol. 2009, 27: 11-16.PubMedCentralCrossRefPubMed
40.
go back to reference Leung J, Pang A, Yuen WH, Kwong YL, Tse EW: Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells. Blood. 2007, 109: 740-746. 10.1182/blood-2006-04-019588CrossRefPubMed Leung J, Pang A, Yuen WH, Kwong YL, Tse EW: Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells. Blood. 2007, 109: 740-746. 10.1182/blood-2006-04-019588CrossRefPubMed
41.
go back to reference Gao L, Gao Y, Li X, Howell P, Kumar R, Su X, Vlassov AV, Piazza GA, Riker AI, Sun D, Xi Y: Aquaporins mediate the chemoresistance of human melanoma cells to arsenite. Mol Oncol. 2012, 6: 81-87. 10.1016/j.molonc.2011.11.001CrossRefPubMed Gao L, Gao Y, Li X, Howell P, Kumar R, Su X, Vlassov AV, Piazza GA, Riker AI, Sun D, Xi Y: Aquaporins mediate the chemoresistance of human melanoma cells to arsenite. Mol Oncol. 2012, 6: 81-87. 10.1016/j.molonc.2011.11.001CrossRefPubMed
42.
go back to reference Renno T, Hahne M, Tschopp J, MacDonald HR: Peripheral T cells undergoing superantigen-induced apoptosis in vivo express B220 and upregulate Fas and Fas ligand. J Exp Med. 1996, 183: 431-437. 10.1084/jem.183.2.431CrossRefPubMed Renno T, Hahne M, Tschopp J, MacDonald HR: Peripheral T cells undergoing superantigen-induced apoptosis in vivo express B220 and upregulate Fas and Fas ligand. J Exp Med. 1996, 183: 431-437. 10.1084/jem.183.2.431CrossRefPubMed
43.
go back to reference Brooks WP, Lynes MA: Effects of hemizygous CD45 expression in the autoimmune Fasl(gld/gld) syndrome. Cell Immunol. 2001, 212: 24-34. 10.1006/cimm.2001.1845CrossRefPubMed Brooks WP, Lynes MA: Effects of hemizygous CD45 expression in the autoimmune Fasl(gld/gld) syndrome. Cell Immunol. 2001, 212: 24-34. 10.1006/cimm.2001.1845CrossRefPubMed
44.
go back to reference Sherman M, Multhoff G: Heat shock proteins in cancer. Ann N Y Acad Sci. 2007, 1113: 192-201. 10.1196/annals.1391.030CrossRefPubMed Sherman M, Multhoff G: Heat shock proteins in cancer. Ann N Y Acad Sci. 2007, 1113: 192-201. 10.1196/annals.1391.030CrossRefPubMed
45.
go back to reference Takayama S, Reed JC, Homma S: Heat-shock proteins as regulators of apoptosis. Oncogene. 2003, 22: 9041-9047. 10.1038/sj.onc.1207114CrossRefPubMed Takayama S, Reed JC, Homma S: Heat-shock proteins as regulators of apoptosis. Oncogene. 2003, 22: 9041-9047. 10.1038/sj.onc.1207114CrossRefPubMed
46.
go back to reference Beere HM: “The stress of dying”: the role of heat shock proteins in the regulation of apoptosis. J Cell Sci. 2004, 117: 2641-2651. 10.1242/jcs.01284CrossRefPubMed Beere HM: “The stress of dying”: the role of heat shock proteins in the regulation of apoptosis. J Cell Sci. 2004, 117: 2641-2651. 10.1242/jcs.01284CrossRefPubMed
47.
go back to reference Gastpar R, Gehrmann M, Bausero MA, Asea A, Gross C, Schroeder JA, Multhoff G: Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. Cancer Res. 2005, 65: 5238-5247. 10.1158/0008-5472.CAN-04-3804PubMedCentralCrossRefPubMed Gastpar R, Gehrmann M, Bausero MA, Asea A, Gross C, Schroeder JA, Multhoff G: Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. Cancer Res. 2005, 65: 5238-5247. 10.1158/0008-5472.CAN-04-3804PubMedCentralCrossRefPubMed
48.
go back to reference Suto R, Srivastava PK: A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science. 1995, 269: 1585-1588. 10.1126/science.7545313CrossRefPubMed Suto R, Srivastava PK: A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science. 1995, 269: 1585-1588. 10.1126/science.7545313CrossRefPubMed
49.
go back to reference Asea A, Kraeft SK, Kurt-Jones EA, Stevenson MA, Chen LB, Finberg RW, Koo GC, Calderwood SK: HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med. 2000, 6: 435-442. 10.1038/74697CrossRefPubMed Asea A, Kraeft SK, Kurt-Jones EA, Stevenson MA, Chen LB, Finberg RW, Koo GC, Calderwood SK: HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nat Med. 2000, 6: 435-442. 10.1038/74697CrossRefPubMed
Metadata
Title
Sensitivity of leukemic T-cell lines to arsenic trioxide cytotoxicity is dependent on the induction of phosphatase B220/CD45R expression at the cell surface
Authors
Mohcine Benbijja
Amine Mellouk
Pierre Bobé
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2014
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-13-251

Other articles of this Issue 1/2014

Molecular Cancer 1/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine